大腸癌篩檢和診斷市場—全球產業規模、佔有率、趨勢、機會和預測（按篩檢、診斷、最終用戶、地區和競爭細分，2020-2030 年）

2024 年全球大腸癌篩檢和診斷市場價值為 150.8 億美元，預計到 2030 年將達到 206.3 億美元，複合年成長率為 5.34%。隨著全球對癌症預防、早期發現和診斷技術進步的認知不斷提高，全球大腸癌篩檢和診斷市場正在經歷顯著成長。大腸直腸癌發生率不斷上升，尤其是 50 歲及以上人群，這推動了對早期和準確篩檢方法的需求。政府和醫療保健組織正在進行宣傳活動，強調常規篩檢的重要性，導致檢測量激增。公私部門合作夥伴關係和醫療保健資助計劃使人們能夠更多地獲得診斷服務，特別是在服務不足的人群中。此外，糞便免疫化學測試 (FIT)、糞便 DNA 測試和血液診斷等非侵入性篩檢方法的接受度不斷提高，使得篩檢更容易被更廣泛的患者群體接受。

技術創新在重塑市場格局中發揮著至關重要的作用。基於人工智慧的大腸鏡系統、數位病理工具和液體活體組織切片技術的開發正在提高檢測準確性並減少侵入性手術的需求。機器學習與診斷影像的結合正在幫助臨床醫生更有效地識別息肉和早期腫瘤。人們對家庭和即時診斷檢測選項的興趣日益濃厚，這也改變了患者的行為，越來越多的人選擇方便、自主的診斷工具。領先的診斷公司正在投資研究，以增強基於生物標記的篩選方法，提供更高的特異性和敏感性，從而開闢新的收入來源。包括大腸直腸癌標記在內的多癌症檢測面板的出現預計將進一步刺激行業內的創新和競爭。

關鍵市場促進因素

技術進步

主要市場挑戰

假陽性和過度診斷

主要市場趨勢

轉向非侵入性測試

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球大腸癌篩檢與診斷市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 透過篩檢（糞便檢查、大腸鏡檢查、乙狀結腸鏡檢查等）
  • 透過診斷（生物標記測試、大腸鏡檢查）
  • 按最終使用者（醫院和診所、臨床實驗室等）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：亞太地區大腸直腸癌篩檢與診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第7章：歐洲大腸癌篩檢與診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第8章：北美大腸癌篩檢與診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第9章：南美洲大腸癌篩檢與診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲大腸直腸癌篩檢和診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章：全球大腸直腸癌篩檢與診斷市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

• Clinical Genomics Technologies Pty Ltd.
• Danaher Corporation
• DiaCarta, Inc
• Eiken Chemical Co., Ltd.
• Epigenomics AG
• Freenome Holdings, Inc.
• Guardant Health, Inc
• FUJIFILM Holdings Corporation
• Novigenix SA
• QuidelOrtho Corporation
• Olympus Corporation
• Lepu Medical Technology (Beijing) Co., Ltd.

第 17 章：策略建議

第18章調查會社について,免責事項

Global Colorectal Cancer Screening and Diagnostic Market was valued at USD 15.08 Billion in 2024 and is expected to reach USD 20.63 Billion in the forecast period with a CAGR of 5.34% through 2030. The Global Colorectal Cancer Screening and Diagnostic Market is witnessing significant growth due to increasing global awareness regarding cancer prevention, early detection, and advancements in diagnostic technologies. Rising incidence rates of colorectal cancer, particularly among individuals aged 50 and above, are propelling the demand for early and accurate screening methods. Governments and healthcare organizations are launching awareness campaigns that emphasize the importance of routine screening, contributing to a surge in testing volumes. Public-private partnerships and healthcare funding initiatives are enabling greater access to diagnostic services, especially in underserved populations. Moreover, the growing acceptance of non-invasive screening methods such as fecal immunochemical tests (FIT), fecal DNA tests, and blood-based diagnostics is making screening more accessible and acceptable to a broader patient demographic.

Technological innovations are playing a vital role in reshaping the market landscape. The development of AI-based colonoscopy systems, digital pathology tools, and liquid biopsy technologies is improving detection accuracy and reducing the need for invasive procedures. Integration of machine learning in diagnostic imaging is assisting clinicians in identifying polyps and early-stage tumors more effectively. Rising interest in home-based and point-of-care testing options is also transforming patient behavior, with more individuals opting for convenient, self-administered diagnostic tools. Leading diagnostic companies are investing in research to enhance biomarker-based screening approaches that offer higher specificity and sensitivity, which is opening new revenue streams. The emergence of multi-cancer detection panels, which include colorectal cancer markers, is expected to further stimulate innovation and competition within the industry.

Key Market Drivers

Advancements in Technology

High-definition (HD) colonoscopy utilizes advanced imaging technology to provide clearer and more detailed images of the colon, enhancing the detection of precancerous polyps and early-stage colorectal cancer during procedures. According to the Centers for Disease Control and Prevention (CDC), in 2019, there were 142,462 reported cases of colon and rectum cancer in the United States, emphasizing the importance of improved detection methods.

Key Market Challenges

False Positives and Over diagnosis

False positives occur when a screening test suggests the presence of colorectal cancer or precancerous lesions when they are not actually present. False positives can cause unnecessary anxiety and stress for patients. They often lead to additional testing and procedures, which can be invasive and carry their own risks. False positives can result in increased healthcare costs due to follow-up tests and procedures. This can strain healthcare resources and increase the financial burden on individuals and healthcare systems. Experiencing a false positive result can deter individuals from participating in future screening, as they may be apprehensive about undergoing another potentially stressful experience. Over diagnosis occurs when a screening test detects a condition that, if left untreated, would not have progressed to clinical significance, or caused harm during the patient's lifetime. Over diagnosis can lead to unnecessary treatment, including surgery, chemotherapy, or radiation therapy. These interventions can have physical and psychological side effects. Treating cases that would not have caused harm can lead to overtreatment, which poses risks to the patient's overall health and quality of life.

Key Market Trends

Shift Towards Non-Invasive Tests

Non-invasive tests, such as stool-based tests or blood tests, are generally more acceptable to patients because they do not involve invasive procedures like colonoscopy. This improved patient acceptance can lead to higher screening participation rates. The avoidance of invasive procedures can reduce patient discomfort and anxiety associated with colorectal cancer screening. This can encourage individuals to undergo testing. Non-invasive tests often require minimal preparation and can be performed at home, making them more convenient for patients. This convenience can lead to higher compliance with screening recommendations. Unlike colonoscopy, which typically requires sedation or anesthesia, non-invasive tests do not involve the use of these medications, eliminating the associated risks and recovery time. Non-invasive tests are generally more cost-effective compared to invasive procedures like colonoscopy, making them an attractive option for both patients and healthcare systems. Some non-invasive tests, such as stool-based tests, can be performed more frequently, allowing for regular monitoring and early detection of changes in colorectal health. Non-invasive tests can be used to reach populations with limited access to healthcare facilities or those who may be hesitant to undergo invasive procedures. Advances in non-invasive screening technologies, such as the development of highly sensitive fecal immunochemical tests (FIT), have improved their ability to detect colorectal cancer and precancerous lesions.

Key Market Players

• Clinical Genomics Technologies Pty Ltd.
• Danaher Corporation
• DiaCarta, Inc.
• Eiken Chemical Co., Ltd.
• Epigenomics AG
• Freenome Holdings, Inc.
• Guardant Health, Inc.
• Lepu Medical Technology (Beijing) Co., Ltd.
• Novigenix SA
• FUJIFILM Holdings Corporation
• Olympus Corporation
• QuidelOrtho Corporation

Report Scope:

In this report, the Global Colorectal Cancer Screening and Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Colorectal Cancer Screening and Diagnostic Market, By Screening:

• Stool-Based Test
• Colonoscopy and Sigmoidoscopy
• Others

Colorectal Cancer Screening and Diagnostic Market, By Diagnostics:

• Biomarker Test
• Colonoscopy

Colorectal Cancer Screening and Diagnostic Market, By End User:

• Hospitals and Clinics
• Clinical Laboratories
• Others

Colorectal Cancer Screening and Diagnostic Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Colorectal Cancer Screening and Diagnostic Market.

Available Customizations:

Global Colorectal Cancer Screening and Diagnostic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Colorectal Cancer Screening and Diagnostic Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Screening (Stool-Based Test, Colonoscopy and Sigmoidoscopy, others)
  • 5.2.2. By Diagnostic (Biomarker Test, Colonoscopy)
  • 5.2.3. By End User (Hospitals and Clinics, Clinical Laboratories, others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Colorectal Cancer Screening and Diagnostic Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Screening
  • 6.2.2. By Diagnostics
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Screening
      • 6.3.1.2.2. By Diagnostics
      • 6.3.1.2.3. By End User
  • 6.3.2. India Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Screening
      • 6.3.2.2.2. By Diagnostics
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Screening
      • 6.3.3.2.2. By Diagnostics
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Screening
      • 6.3.4.2.2. By Diagnostics
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Colorectal Cancer Screening and Diagnostic Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Screening
      • 6.3.5.2.2. By Diagnostics
      • 6.3.5.2.3. By End User

7. Europe Colorectal Cancer Screening and Diagnostic Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Screening
  • 7.2.2. By Diagnostics
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Screening
      • 7.3.1.2.2. By Diagnostics
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Screening
      • 7.3.2.2.2. By Diagnostics
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Screening
      • 7.3.3.2.2. By Diagnostics
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Screening
      • 7.3.4.2.2. By Diagnostics
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Colorectal Cancer Screening and Diagnostic Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Screening
      • 7.3.5.2.2. By Diagnostics
      • 7.3.5.2.3. By End User

8. North America Colorectal Cancer Screening and Diagnostic Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Screening
  • 8.2.2. By Diagnostics
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Colorectal Cancer Screening and Diagnostic Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Screening
      • 8.3.1.2.2. By Diagnostics
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Colorectal Cancer Screening and Diagnostic Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Screening
      • 8.3.2.2.2. By Diagnostics
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Colorectal Cancer Screening and Diagnostic Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Screening
      • 8.3.3.2.2. By Diagnostics
      • 8.3.3.2.3. By End User

9. South America Colorectal Cancer Screening and Diagnostic Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Screening
  • 9.2.2. By Diagnostics
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Colorectal Cancer Screening and Diagnostic Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Screening
      • 9.3.1.2.2. By Diagnostics
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Colorectal Cancer Screening and Diagnostic Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Screening
      • 9.3.2.2.2. By Diagnostics
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Colorectal Cancer Screening and Diagnostic Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Screening
      • 9.3.3.2.2. By Diagnostics
      • 9.3.3.2.3. By End User

10. Middle East and Africa Colorectal Cancer Screening and Diagnostic Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Screening
  • 10.2.2. By Diagnostics
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Colorectal Cancer Screening and Diagnostic Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Screening
      • 10.3.1.2.2. By Diagnostics
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Colorectal Cancer Screening and Diagnostic Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Screening
      • 10.3.2.2.2. By Diagnostics
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Colorectal Cancer Screening and Diagnostic Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Screening
      • 10.3.3.2.2. By Diagnostics
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Colorectal Cancer Screening and Diagnostic Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Clinical Genomics Technologies Pty Ltd.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Danaher Corporation
• 16.3. DiaCarta, Inc
• 16.4. Eiken Chemical Co., Ltd.
• 16.5. Epigenomics AG
• 16.6. Freenome Holdings, Inc.
• 16.7. Guardant Health, Inc
• 16.8. FUJIFILM Holdings Corporation
• 16.9. Novigenix SA
• 16.10. QuidelOrtho Corporation
• 16.11. Olympus Corporation
• 16.12. Lepu Medical Technology (Beijing) Co., Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer